



HBV Forum 6
Thursday, November 7, 2019

12:30 PM Registration & Lunch Reception		
1:30 PM	Welcome and Housekeeping	<i>Jessica Weber, Forum for Collaborative Research</i>
1:35 PM	Introductory Remarks	<i>Veronica Miller, Forum for Collaborative Research</i>
1:40 PM Session I: Field Updates (a)		
Moderators: <i>Veronica Miller, Forum for Collaborative Research & Robert Gish, Robert G. Gish Consultants LLC</i>		
1:40 PM	What's Hot at The Liver Meeting?	<i>Edward Gane, University of Auckland</i>
1:50 PM	Member Updates	
	- FDA Draft Guidance: Chronic Hepatitis D Virus Infection	<i>Aimee Hodowanec, U.S. Food & Drug Administration</i>
	- Patient Focused Drug Development Meeting	<i>Chari Cohen, Hepatitis B Foundation</i>
	- Hepatitis B Study Update	<i>Scott Harris, Altimmune, Inc.</i>
2:05 PM	Discussion	<i>All</i>
2:15 PM Session II: Regulatory Consideration Panel Topics		
Moderators: <i>Veronica Miller, Forum for Collaborative Research & Marion Peters, ACTG Chicago</i>		
		<i>Stephanie Buchholz, Federal Institute for Drugs & Medical Devices Jordan Feld, University Health Network Douglas Mayers, Antios Therapeutics</i>
2:15 PM	Panel 1: Potential Intermediate Stages on the Way to "Cure"	<i>Poonam Mishra, U.S. Food & Drug Administration Su Wang, Saint Barnabas Medical Center & World Hepatitis Alliance Cynthia Wat, Roche Products Ltd Gabriel Westman, Swedish Medical Products Agency</i>
	Panel 2: Stopping Treatment	<i>Mark Avigan, U.S. Food & Drug Administration</i>
2:55 PM	- When and How Long?	<i>Stephanie Buchholz, Federal Institute for Drugs & Medical Devices</i>
	- What to Monitor?	<i>Eric Donaldson, U.S. Food & Drug Administration</i>
	- mRNA & Other Markers	<i>Pietro Lampertico, University of Milan</i>
	- Length of Follow-up	<i>Ed Marins, Roche</i>
	- Monitoring for Resistance	<i>Michael Ninburg, Hepatitis Education Project</i>
3:40 PM Break		
4:10 PM	Panel 3: Core Inhibitor Sub-Classes and Mechanisms of Action	<i>Eric Donaldson, U.S. Food & Drug Administration John Fry, Aligos Therapeutics Lu Gao, Roche Oliver Lenz, Janssen</i>

4:25 PM Session III: HBV Forum Updates

Moderator: *Veronica Miller, Forum for Collaborative Research*

4:25 PM	Immune Monitoring Working Group	<i>Sara Ferrando-Martinez, AstraZeneca Adam Gehring, Toronto Centre for Liver Disease</i>
4:35 PM	Liver Safety Monitoring Manuscript (JVH)	<i>Robert Fontana, University of Michigan</i>
4:40 PM	HBsAg Loss Meta-Analysis	<i>Hannah Choi, Toronto Centre for Liver Disease</i>
4:50 PM	Planned Collaboration: Stop Nuc Studies	<i>Harry Janssen, Toronto Centre for Liver Disease, University Health Network Hannah Choi, Toronto Centre for Liver Disease</i>
5:05 PM	Discussion	<i>All</i>

5:15 PM Session IV: How Important is Viral and Patient Heterogeneity?

Moderator: *Anuj Gaggar, Gilead Sciences*

5:15 PM	Panel 4: Implications for Clinical Trial Design	<i>Gavin Cloherty, Abbott Labs Eric Donaldson, U.S. Food & Drug Administration Saeed Hamid, Aga Khan University Mala Maini, University College London Leen-Jan van Doorn, DDL Diagnostic Laboratory</i>
---------	--	---

5:35 PM Session V: Field Updates (b) and Special Debate

Moderators: *Harry Janssen, Toronto Centre for Liver Disease, University Health Network & Timothy Block, Baruch S. Blumberg Institute and Hepatitis B Foundation*

5:35 PM	ICE-HBV: Global Fund & Messaging Briefing	<i>Veronica Miller, Forum for Collaborative Research Massimo Levrero, ICE-HBV Board</i>
5:50 PM	Special Debate: HBV Treatment Guidelines vs. Test-Treat All	<i>Homie Razavi, Center for Disease Analysis Foundation Brian McMahon, Alaska Native Tribal Health Consortium</i>
6:10 PM	Discussion	<i>All</i>
6:20 PM	Wrap Up and Next Steps	

6:30 PM Evening Networking Reception

**Evening Networking Reception
6:30 PM – 9:00 PM
Grand Master Ballroom & Foyer**

Please join us for a networking reception to be held immediately following the close of the meeting. *Members of the Liver Forum and PSC Forum will be able to join the reception starting at 7:00pm*